Over the history of the Company, yes...a lot of dreams, but not much follow thru. For *reasons*, that may be changing...
In the past two-ish years, the Company has made more concrete steps to actually delivering on its promises - Obtaining third party funding for expansion (which, while ultimately dilutative following a conversion of pref shares, did not require toxic convertible notes); using that funding to obtain potentially marketable IP; and bringing in new advisors/officers with both a vested interest and the requisite skillset to capitalize on that IP to name a few.
There are still some question marks - what are the status/use cases for the new facilities? Why are we only seeing a portion of the pref in the 2023 fins? Shouldn't there be more expenses related to facilities/loans/COGS on the fins? Where do all of the previously announced 'just around the corner' deals stand, and why have we not seen any tangible impact on top/bottom line?
SHMN is the prototypical pink pharma company that wants to become legitimate, but IMHO has an above average shot of doing so. They haven't buried themselves in toxic financing, maintain a pretty good balance sheet, and seem to have found a legitimately novel product to bring to market. I'd love to see a continuation of the migration to SMEs within the leadership structure who can drive the company forward, and hope that they can bring in some technical sales folks with the connections to market the new IP solutions.
All in all, like a few on this board I hold a decent bag, and have enough interest in what's coming to keep holding. My basis and need for liquidity are both pretty low, so I can afford to do so. YMMV.
GLTA
